Begin crossing over control patients in the U.S. AMT-130 study
Delivered by the deadline
Under re-examination This entry has been challenged and is being re-checked against the sources.
- Announced
- 8 Aug 2022
- Due
- 30 Sep 2022
- Delivered
- July 2022
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“expects to begin crossing over control patients from the U.S. study at this dose in the third quarter of 2022”
What we found
Evidence strength A What the grades mean
The company began the crossover process for control patients in the U.S. AMT-130 study in July 2022, which is within the third quarter of 2022.
-
A uniQure N.V. 10-Q filed 2023-08-01
“In July 2022, we began crossing over patients in the high-dose cohort who received the imitation surgical procedure.” ✓ confirmed on the page
Checked 1 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Crossover of control patients
- Where
- U.S.
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2022-QURE-001809 · Corrections policy